Oscotec Inc.

KOSDAQ:A039200 Stock Report

Market Cap: ₩1.5t

Oscotec Past Earnings Performance

Past criteria checks 5/6

Oscotec has been growing earnings at an average annual rate of 46.6%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 39.3% per year. Oscotec's return on equity is 31.3%, and it has net margins of 54.7%.

Key information

46.60%

Earnings growth rate

49.00%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate39.34%
Return on equity31.32%
Net Margin54.71%
Last Earnings Update31 Mar 2026

Recent past performance updates

Analysis Article • Mar 30

Oscotec's (KOSDAQ:039200) Earnings Are Weaker Than They Seem

Investors were disappointed with Oscotec Inc.'s ( KOSDAQ:039200 ) earnings, despite the strong profit numbers. Our...

Recent updates

Analysis Article • Mar 30

Oscotec's (KOSDAQ:039200) Earnings Are Weaker Than They Seem

Investors were disappointed with Oscotec Inc.'s ( KOSDAQ:039200 ) earnings, despite the strong profit numbers. Our...
Analysis Article • Sep 19

Oscotec Inc.'s (KOSDAQ:039200) 32% Jump Shows Its Popularity With Investors

Oscotec Inc. ( KOSDAQ:039200 ) shares have continued their recent momentum with a 32% gain in the last month alone...
Analysis Article • Aug 13

Despite Lacking Profits Oscotec (KOSDAQ:039200) Seems To Be On Top Of Its Debt

KOSDAQ:A039200 1 Year Share Price vs Fair Value Explore Oscotec's Fair Values from the Community and select yours...
Analysis Article • Jul 03

Oscotec Inc. (KOSDAQ:039200) Not Flying Under The Radar

When you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
Analysis Article • Mar 26

Oscotec Inc. (KOSDAQ:039200) Looks Just Right With A 26% Price Jump

Oscotec Inc. ( KOSDAQ:039200 ) shares have continued their recent momentum with a 26% gain in the last month alone...
Analysis Article • Feb 16

Rock star Growth Puts Oscotec (KOSDAQ:039200) In A Position To Use Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 20

With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay For

The Oscotec Inc. ( KOSDAQ:039200 ) share price has fared very poorly over the last month, falling by a substantial 38...
Analysis Article • Aug 07

Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Apr 26

Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 23

Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?

Every investor in Oscotec Inc. ( KOSDAQ:039200 ) should be aware of the most powerful shareholder groups. Insiders...
Analysis Article • Jan 19

If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns

It might be of some concern to shareholders to see the Oscotec Inc. ( KOSDAQ:039200 ) share price down 27% in the last...
Analysis Article • Dec 15

Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Revenue & Expenses Breakdown

How Oscotec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A039200 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26101,55055,55918,46928,447
31 Dec 2599,83952,34315,98527,637
30 Sep 2523,235-13,1399,30026,140
30 Jun 2543,3454,25410,28025,047
31 Mar 2534,88238511,63621,666
31 Dec 2434,00887710,56021,429
30 Sep 2431,977-4,88213,10220,010
30 Jun 244,618-26,30511,63022,053
31 Mar 244,864-24,4459,19724,473
31 Dec 234,951-24,2808,46924,907
30 Sep 236,019-18,2157,86022,195
30 Jun 235,436-20,1667,01221,959
31 Mar 235,180-22,0476,87121,643
31 Dec 225,062-24,4306,21923,343
30 Sep 224,848-25,2135,56622,643
30 Jun 224,588-25,0625,47922,137
31 Mar 224,039-24,3715,21321,366
31 Dec 213,903-26,2635,54022,709
30 Sep 2128,955-17,7346,09834,754
30 Jun 2128,885-18,3025,90534,432
31 Mar 2143,415-7,4675,99735,724
31 Dec 2043,471-4,3575,70932,787
30 Sep 2018,182-15,5015,41122,352
30 Jun 2018,634-12,3465,57920,333
31 Mar 204,221-24,5848,05917,483
31 Dec 194,369-22,6017,91015,409
30 Sep 1918,885-4,9097,15211,579
30 Jun 1918,782-5,3936,50312,292
31 Mar 1918,657-2583,16710,171
31 Dec 1818,7033,3712,7066,970
30 Sep 183,917-8,4152,7507,191
30 Jun 183,809-5,5372,6854,457
31 Mar 183,721-5,3612,7144,205
31 Dec 173,908-5,8572,7934,821
30 Sep 174,600-7,4652,4308,437
30 Jun 174,343-7,0132,3047,735
31 Mar 173,968-9,4852,7156,795
31 Dec 163,554-8,8511,8236,547
30 Sep 166,816-5,2562,5921,823
30 Jun 1611,714-2,9853,4691,830
31 Mar 1614,8952593,8562,341
31 Dec 1518,3363955,0721,998
30 Sep 1517,441-1,0635,5392,159
30 Jun 1516,514-2,6155,5582,220

Quality Earnings: A039200 has a high level of non-cash earnings.

Growing Profit Margin: A039200's current net profit margins (54.7%) are higher than last year (1.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A039200 has become profitable over the past 5 years, growing earnings by 46.6% per year.

Accelerating Growth: A039200's earnings growth over the past year (14328.1%) exceeds its 5-year average (46.6% per year).

Earnings vs Industry: A039200 earnings growth over the past year (14328.1%) exceeded the Pharmaceuticals industry 25.5%.

Return on Equity

High ROE: A039200's Return on Equity (31.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 10:55
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oscotec Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Haesoon KwonEugene Investment & Securities Co Ltd.
Sangsoo KimGoldman Sachs
Wan KuiM Securities